News round-up for 31 July – 4 August by DDW Digital Content Editor Diana Spencer.
The pace of innovation in cancer drug discovery showed no signs of slowing this week, with several pretty momentous discoveries boosting research in the sector. These include the creation of a compound that can block the spread of cancer and the discovery that PARP inhibitors could be effective in a new group of patients.
The top stories:
Promontory Therapeutics expands Phase II mCRPC trial
Promontory Therapeutics has treated its first patients in France as part of the ongoing Phase II clinical trial of PT-112 in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC).
Scientists create compound that can block cancer metastasis
Researchers from the University of Liverpool, UK, have created a biomedical compound that has the potential to stop the spread of breast cancer.
RNA-based immunotherapy eradicates melanoma tumours
Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma.
Sarcoma ‘Rosetta stone’ could bring new era of personalisation
Scientists have unveiled the first and largest encyclopaedia of protein alterations in soft tissue sarcomas – opening the door to a new era of understanding and treatment for this group of rare cancers.
PARP inhibitor use could be extended to more cancer patients
New findings suggest PARP inhibitor drugs, used to treat cancer patients who have an altered BRCA1 or BRCA2 gene, may also be effective for patients which have changes in the SF3B1 gene.
